PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer

Charles M. Quick, Gang Ning, Jonathan Bijron, Anna Laury, Tay Seok Wei, Eleanor Y. Chen, Sara O. Vargas, Rebecca Betensky, Frank D. McKeon, Wa Xian, Christopher P. Crum

Research output: Contribution to journalArticle

Abstract

With the exception of germ-line mutations in ovarian cancer susceptibility genes, genetic predictors for women destined for ovarian serous cancer cannot be identified in advance of malignancy. We recently showed that benign secretory cell outgrowths (SCOUTs) in the oviduct are increased in frequency with concurrent serous cancer and typically lack PAX2 expression (PAX2-null). The present study examined the relationship of PAX2-null SCOUTs to high-grade serous cancers by comparing oviducts from women with benign gynecologic conditions and high-grade serous cancers. PAX2-null SCOUTs were identified by immunostaining and computed as a function of location, frequency (F) per number of cross-sections examined, and age. Six hundred thirty-nine cross-sections from 35 serous cancers (364) and 35 controls (275) were examined. PAX2-null SCOUTs consisted of discrete linear stretches of altered epithelium ranging from cuboidal/columnar, to pseudostratified, the latter including ciliated differentiation. They were evenly distributed among proximal and fimbrial tubal sections. One hundred fourteen (F=0.31) and 45 (F=0.16) PAX2-null SCOUTs were identified in cases and controls, respectively. Mean individual case-specific frequencies for cases and controls were 0.39 and 0.14, respectively. SCOUT frequency increased significantly with age in both groups (P=0.01). However, when adjusted for age and the number of sections examined, the differences in frequency between cases and controls remained significant at P=0.006. This study supports a relationship between discrete PAX2 gene dysregulation in the oviduct and both increasing age and, more significantly, the presence of co-existing serous cancer. We propose a unique co-variable in benign oviductal epithelium-the PAX2-null SCOUT-that reflects underlying dysregulation in genes linked to serous neoplasia.

Original languageEnglish (US)
Pages (from-to)449-455
Number of pages7
JournalModern Pathology
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Pelvic Neoplasms
Null Lymphocytes
Oviducts
Neoplasms
Ovarian Neoplasms
Epithelium
Germ-Line Mutation
Neoplasm Genes
Genetic Predisposition to Disease
Genes

Keywords

  • fallopian tube
  • ovarian cancer
  • oviduct
  • PAX2
  • serous cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Quick, C. M., Ning, G., Bijron, J., Laury, A., Wei, T. S., Chen, E. Y., ... Crum, C. P. (2012). PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. Modern Pathology, 25(3), 449-455. https://doi.org/10.1038/modpathol.2011.175

PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. / Quick, Charles M.; Ning, Gang; Bijron, Jonathan; Laury, Anna; Wei, Tay Seok; Chen, Eleanor Y.; Vargas, Sara O.; Betensky, Rebecca; McKeon, Frank D.; Xian, Wa; Crum, Christopher P.

In: Modern Pathology, Vol. 25, No. 3, 01.03.2012, p. 449-455.

Research output: Contribution to journalArticle

Quick, CM, Ning, G, Bijron, J, Laury, A, Wei, TS, Chen, EY, Vargas, SO, Betensky, R, McKeon, FD, Xian, W & Crum, CP 2012, 'PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer', Modern Pathology, vol. 25, no. 3, pp. 449-455. https://doi.org/10.1038/modpathol.2011.175
Quick, Charles M. ; Ning, Gang ; Bijron, Jonathan ; Laury, Anna ; Wei, Tay Seok ; Chen, Eleanor Y. ; Vargas, Sara O. ; Betensky, Rebecca ; McKeon, Frank D. ; Xian, Wa ; Crum, Christopher P. / PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. In: Modern Pathology. 2012 ; Vol. 25, No. 3. pp. 449-455.
@article{add1c5488526467aa8e8905a00497640,
title = "PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer",
abstract = "With the exception of germ-line mutations in ovarian cancer susceptibility genes, genetic predictors for women destined for ovarian serous cancer cannot be identified in advance of malignancy. We recently showed that benign secretory cell outgrowths (SCOUTs) in the oviduct are increased in frequency with concurrent serous cancer and typically lack PAX2 expression (PAX2-null). The present study examined the relationship of PAX2-null SCOUTs to high-grade serous cancers by comparing oviducts from women with benign gynecologic conditions and high-grade serous cancers. PAX2-null SCOUTs were identified by immunostaining and computed as a function of location, frequency (F) per number of cross-sections examined, and age. Six hundred thirty-nine cross-sections from 35 serous cancers (364) and 35 controls (275) were examined. PAX2-null SCOUTs consisted of discrete linear stretches of altered epithelium ranging from cuboidal/columnar, to pseudostratified, the latter including ciliated differentiation. They were evenly distributed among proximal and fimbrial tubal sections. One hundred fourteen (F=0.31) and 45 (F=0.16) PAX2-null SCOUTs were identified in cases and controls, respectively. Mean individual case-specific frequencies for cases and controls were 0.39 and 0.14, respectively. SCOUT frequency increased significantly with age in both groups (P=0.01). However, when adjusted for age and the number of sections examined, the differences in frequency between cases and controls remained significant at P=0.006. This study supports a relationship between discrete PAX2 gene dysregulation in the oviduct and both increasing age and, more significantly, the presence of co-existing serous cancer. We propose a unique co-variable in benign oviductal epithelium-the PAX2-null SCOUT-that reflects underlying dysregulation in genes linked to serous neoplasia.",
keywords = "fallopian tube, ovarian cancer, oviduct, PAX2, serous cancer",
author = "Quick, {Charles M.} and Gang Ning and Jonathan Bijron and Anna Laury and Wei, {Tay Seok} and Chen, {Eleanor Y.} and Vargas, {Sara O.} and Rebecca Betensky and McKeon, {Frank D.} and Wa Xian and Crum, {Christopher P.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1038/modpathol.2011.175",
language = "English (US)",
volume = "25",
pages = "449--455",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer

AU - Quick, Charles M.

AU - Ning, Gang

AU - Bijron, Jonathan

AU - Laury, Anna

AU - Wei, Tay Seok

AU - Chen, Eleanor Y.

AU - Vargas, Sara O.

AU - Betensky, Rebecca

AU - McKeon, Frank D.

AU - Xian, Wa

AU - Crum, Christopher P.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - With the exception of germ-line mutations in ovarian cancer susceptibility genes, genetic predictors for women destined for ovarian serous cancer cannot be identified in advance of malignancy. We recently showed that benign secretory cell outgrowths (SCOUTs) in the oviduct are increased in frequency with concurrent serous cancer and typically lack PAX2 expression (PAX2-null). The present study examined the relationship of PAX2-null SCOUTs to high-grade serous cancers by comparing oviducts from women with benign gynecologic conditions and high-grade serous cancers. PAX2-null SCOUTs were identified by immunostaining and computed as a function of location, frequency (F) per number of cross-sections examined, and age. Six hundred thirty-nine cross-sections from 35 serous cancers (364) and 35 controls (275) were examined. PAX2-null SCOUTs consisted of discrete linear stretches of altered epithelium ranging from cuboidal/columnar, to pseudostratified, the latter including ciliated differentiation. They were evenly distributed among proximal and fimbrial tubal sections. One hundred fourteen (F=0.31) and 45 (F=0.16) PAX2-null SCOUTs were identified in cases and controls, respectively. Mean individual case-specific frequencies for cases and controls were 0.39 and 0.14, respectively. SCOUT frequency increased significantly with age in both groups (P=0.01). However, when adjusted for age and the number of sections examined, the differences in frequency between cases and controls remained significant at P=0.006. This study supports a relationship between discrete PAX2 gene dysregulation in the oviduct and both increasing age and, more significantly, the presence of co-existing serous cancer. We propose a unique co-variable in benign oviductal epithelium-the PAX2-null SCOUT-that reflects underlying dysregulation in genes linked to serous neoplasia.

AB - With the exception of germ-line mutations in ovarian cancer susceptibility genes, genetic predictors for women destined for ovarian serous cancer cannot be identified in advance of malignancy. We recently showed that benign secretory cell outgrowths (SCOUTs) in the oviduct are increased in frequency with concurrent serous cancer and typically lack PAX2 expression (PAX2-null). The present study examined the relationship of PAX2-null SCOUTs to high-grade serous cancers by comparing oviducts from women with benign gynecologic conditions and high-grade serous cancers. PAX2-null SCOUTs were identified by immunostaining and computed as a function of location, frequency (F) per number of cross-sections examined, and age. Six hundred thirty-nine cross-sections from 35 serous cancers (364) and 35 controls (275) were examined. PAX2-null SCOUTs consisted of discrete linear stretches of altered epithelium ranging from cuboidal/columnar, to pseudostratified, the latter including ciliated differentiation. They were evenly distributed among proximal and fimbrial tubal sections. One hundred fourteen (F=0.31) and 45 (F=0.16) PAX2-null SCOUTs were identified in cases and controls, respectively. Mean individual case-specific frequencies for cases and controls were 0.39 and 0.14, respectively. SCOUT frequency increased significantly with age in both groups (P=0.01). However, when adjusted for age and the number of sections examined, the differences in frequency between cases and controls remained significant at P=0.006. This study supports a relationship between discrete PAX2 gene dysregulation in the oviduct and both increasing age and, more significantly, the presence of co-existing serous cancer. We propose a unique co-variable in benign oviductal epithelium-the PAX2-null SCOUT-that reflects underlying dysregulation in genes linked to serous neoplasia.

KW - fallopian tube

KW - ovarian cancer

KW - oviduct

KW - PAX2

KW - serous cancer

UR - http://www.scopus.com/inward/record.url?scp=84857555620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857555620&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.175

DO - 10.1038/modpathol.2011.175

M3 - Article

VL - 25

SP - 449

EP - 455

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 3

ER -